Sign inJoin waitlistJoin the waitlist

Omar Atiq

Distinguished Professor · University of Arkansas for Medical Sciences (UAMS) College of Medicine

Credentials: · · · · ·

History

University of Arkansas for Medical Sciences (UAMS) College of Medicine
Present

Hematology and Medical Oncology
Memorial Sloan Kettering Cancer Center
1989–1992
diploma: University of the State of New York
1986–1989
Internal Medicine
Loyola University Medical Center
1983–1986
BACHA KHAN MED COLL, KHYBER MEDICAL UNIV, MARDAN, PAKISTAN
1979–1983

Research

FAMTX versus etoposide, doxorubicin, and cisplatin: a random assignment trial in gastric cancer
Journal of Clinical Oncology · 1992 · 287 citations
Phase II trial of postoperative adjuvant intraperitoneal cisplatin and fluorouracil and systemic fluorouracil chemotherapy in patients with resected gastric cancer
Journal of Clinical Oncology · 1993 · First of 10 authors · 55 citations
Treatment of unresectable primary liver cancer with intrahepatic fluorodeoxyuridine and mitomycin C through an implantable pump
Cancer · 1992 · First of 4 authors · 55 citations

David Hilden
7 papers
DK
David Kelsen
3 papers
Konstantinos Arnaoutakis
3 papers
Mayumi Nakagawa
3 papers
Emre Vural
2 papers
Ginger Gilmore-Brown
2 papers
Jumin Sunde
2 papers
LS
Leonard Saltz
2 papers
Mohammad Atiq
2 papers · 2 as a resident
MB
Murray Brennan
2 papers
NK
Nancy Kemeny
2 papers
OA
Osman Atiq
2 papers · 1 as a resident

Clinical trials

Candida Therapeutic Vaccine in Head and Neck Cancer Patients to Reduce Recurrence
Principal investigator · Recruiting · Phase 2
University of Arkansas
2024–2032
A Phase I/II Clinical Trial of PepCan in Head and Neck Cancer Patients
Principal investigator · Completed · Phase 1, Phase 2
University of Arkansas
2019–2025
Testing the Addition of Anti-Cancer Drug, Cetuximab, to Standard of Care Treatment (Pembrolizumab) for Returning or Spreading Head and Neck Cancer After Previous Treatment
Site PI · Recruiting · Phase 3
National Cancer Institute (NCI)
2025–2029
BiCaZO: A Study Combining Two Immunotherapies (Cabozantinib and Nivolumab) to Treat Patients With Advanced Melanoma or Squamous Cell Head and Neck Cancer, an immunoMATCH Pilot Study
Site PI · Recruiting · Phase 2
National Cancer Institute (NCI)
2022–2027